Is routine post-procedural anticoagulation warranted after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction? Insights from the HORIZONS-AMI trial

Eur Heart J Acute Cardiovasc Care. 2017 Oct;6(7):650-658. doi: 10.1177/2048872615592246. Epub 2015 Jun 29.

Abstract

Aim: Post-procedural anticoagulation (AC) for routine prophylaxis may be administered after primary percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI), but the risks and benefits of this practice are uncertain. We therefore sought to assess the utility of routine post-procedural AC after primary PCI.

Methods and results: Patients undergoing primary PCI in the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial were grouped according to whether they received post-PCI AC for routine prophylaxis. Outcomes were assessed using propensity-adjusted multivariable analysis. Among 2932 patients in whom primary PCI for STEMI was performed, 869 (29.6%) received post-PCI AC for routine prophylaxis (median duration four days) and 2063 (70.4%) received no post-PCI AC. Time from PCI to ambulation was similar in both groups (median 0.9 vs 1.0 days, p=0.40), although hospitalization was prolonged in patients receiving AC for routine prophylaxis (median 6.0 vs 4.0 days, p<0.0001). After propensity-adjustment, patients who received and did not receive AC for routine prophylaxis after PCI experienced similar rates of 30-day adverse ischemic and major bleeding events. Deep venous thrombosis or pulmonary emboli developed rarely (0.3%) within 30 days, and were not significantly reduced by use of post-PCI AC for routine prophylaxis.

Conclusions: In this large-scale prospective study, use of post-procedural AC for routine prophylaxis was relatively common, and was not associated with improved clinical outcomes, although the duration of hospitalization was prolonged. These data suggest that post-PCI AC for routine prophylaxis may not provide benefit after successful primary PCI in patients in whom early ambulation is likely.

Keywords: ST-segment elevation myocardial infarction; anticoagulation; bleeding; percutaneous coronary intervention.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Antithrombins / administration & dosage*
  • Aspirin / administration & dosage
  • Clopidogrel
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Drug-Eluting Stents
  • Electrocardiography
  • Female
  • Fibrinolytic Agents / administration & dosage*
  • Follow-Up Studies
  • Heparin / administration & dosage
  • Hirudins / administration & dosage
  • Humans
  • Male
  • Middle Aged
  • Peptide Fragments / administration & dosage
  • Percutaneous Coronary Intervention
  • Platelet Aggregation Inhibitors / administration & dosage*
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
  • Postoperative Care / methods*
  • Postoperative Complications / epidemiology
  • Postoperative Complications / prevention & control*
  • Prospective Studies
  • Recombinant Proteins / administration & dosage
  • ST Elevation Myocardial Infarction / therapy*
  • Secondary Prevention / methods
  • Survival Rate / trends
  • Thrombolytic Therapy / methods*
  • Ticlopidine / administration & dosage
  • Ticlopidine / analogs & derivatives
  • Treatment Outcome

Substances

  • Antithrombins
  • Fibrinolytic Agents
  • Hirudins
  • Peptide Fragments
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Recombinant Proteins
  • Heparin
  • Clopidogrel
  • Ticlopidine
  • Aspirin
  • bivalirudin